Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study

被引:31
|
作者
Mundwiler, Matthew L. [2 ]
Mei, Ling [1 ]
Landers, Carol J. [1 ]
Reveille, John D. [3 ]
Targan, Stephan [1 ]
Weisman, Michael H. [1 ]
机构
[1] Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Los Angeles, CA 90048 USA
[2] Rockford Orthoped Associates, Rockford, IL 61107 USA
[3] Univ Texas Hlth Sci Ctr, Houston, TX 77030 USA
关键词
CROHNS-DISEASE; SACCHAROMYCES-CEREVISIAE; MICROBIAL ANTIGENS; PSOAS COHORT; ANTIBODIES; ASSOCIATION; PREVALENCE; SPONDYLOARTHROPATHIES; AUTOANTIBODIES; ARTHRITIS;
D O I
10.1186/ar2866
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) share similarities and are classified as spondyloarthropathies. In IBD, anti-Saccharomyces cerevisiae antibody (ASCA), anti-I2 (associated with anti-Pseudomonas activity), anti-Escherichia coli outer membrane porin C (anti-OmpC), anti-flagellin (anti-CBir1), and antineutrophil cytoplasmic antibodies (ANCA) possess clinical significance. Because of the overlap between the two conditions, a pilot study was designed to compare the frequency of these antibodies in AS patients compared to normal controls. Methods Serum stored from 80 AS patients and 80 control subjects was available for analysis. ASCA, anti-I2, anti-OmpC, anti-CBir1, and ANCA studies were completed on all serum samples using Enzyme-Linked Immunosorbent Assay (ELISA) methodology. The following analyses were performed: comparison of positivity based on the established values in IBD, median values, the number of subjects in each serology in the 4(th) quartile of a normal distribution, and the mean quartile sum of all the antibodies. Results There was no difference in positivity rates between AS and control groups with the established IBD values. The median anti-I2 response was significantly higher in AS than in controls (11.78 vs 7.86, p = 0.017). Significantly more AS patients had quartile scores of 4 for the following antibody responses: ASCA IgG (26% vs 13%, p = 0.016, OR = 2.49, CI 1.168-5.313), ASCA IgG and IgA (27% vs 12%, p = 0.006, OR = 2.9, CI: 1.342-6.264), and anti-I2 (25% vs 14%, p = 0.0424, OR = 2.15, CI: 1.018-4.538). The mean quartile sum of the antibody responses was elevated in AS patients when ANCA was excluded (10.526 vs 9.519, p = 0.03). When ANCA was included, this difference lost significance. Conclusions The data from this pilot study points towards mucosal dysregulation as an important pathway in AS. We were able to demonstrate that anti-I2 could play a pathologic role in AS. The elevated mean total antibody response being significant only with ANCA exclusion is consistent with the histopathological evidence that intestinal inflammation in AS is similar to Crohn's disease. To better define the roles of these antibodies in AS, larger studies with more precisely defined patient characteristics are required.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
    Matthew L Mundwiler
    Ling Mei
    Carol J Landers
    John D Reveille
    Stephan Targan
    Michael H Weisman
    Arthritis Research & Therapy, 11
  • [2] Incidence of inflammatory bowel disease in patients with ankylosing spondylitis
    Lai, Shih-Wei
    Kuo, Yu-Hung
    Liao, Kuan-Fu
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (09)
  • [3] INFLAMMATORY BOWEL DISEASE IN ANKYLOSING SPONDYLITIS
    JAYSON, MIV
    SALMON, PR
    HARRISON, WJ
    GUT, 1970, 11 (06) : 506 - +
  • [4] THE PREVALENCE OF ENTHESOPATHY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND ANKYLOSING SPONDYLITIS BY ULTRASONOGRAPHY
    Lee, Y. A.
    Kim, J. Y.
    Lee, S. H.
    Hong, S. J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (04) : 635 - 635
  • [5] THE PREVALENCE OF ENTHESOPATHY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND ANKYLOSING SPONDYLITIS BY ULTRASONOGRAPHY
    Lee, Yeon-Ah
    Lee, Sang-Hoon
    RHEUMATOLOGY, 2012, 51 : I32 - I32
  • [6] ANKYLOSING-SPONDYLITIS AND INFLAMMATORY BOWEL-DISEASE .1. PREVALENCE OF INFLAMMATORY BOWEL-DISEASE IN PATIENTS SUFFERING FROM ANKYLOSING-SPONDYLITIS
    MEUWISSEN, SGM
    DEKKERSAEYS, BJ
    AGENANT, D
    TYTGAT, GNJ
    ANNALS OF THE RHEUMATIC DISEASES, 1978, 37 (01) : 30 - 32
  • [7] Inflammatory bowel disease, ankylosing spondylitis, and IgA nephropathy
    de Moura, CG
    de Souza, TGGDSP
    Testagrossa, L
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2006, 12 (02) : 106 - 107
  • [8] SECUKINUMAB AND INCIDENT INFLAMMATORY BOWEL DISEASE IN ANKYLOSING SPONDYLITIS
    Nilsson, P. D.
    Sawhney, H.
    Castillo, M.
    Gensler, L.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2020, 68 : A15 - A16
  • [9] Advances in Research of Ankylosing Spondylitis with Inflammatory Bowel Disease
    Xuhong ZHANG
    Lamei ZHOU
    Medicinal Plant, 2023, (01) : 103 - 105
  • [10] THE FREQUENCY OF INFLAMMATORY BOWEL DISEASES IN PATIENTS WITH ANKYLOSING SPONDYLITIS
    Lukina, G.
    Kulakova, P.
    Savenkova, N.
    Volnukhin, E.
    Kovshik, A.
    Alexandrova, E.
    Novikov, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1643 - 1643